Market data not licensed for redistribution.
Qurient
115180 · KOSDAQ · R&D in Natural Sciences & Engineering
Close
Source: Financial Services Commission stock price data (data.go.kr), updated once a day.
Daily price, 1 year
Key statistics
Market cap (KRW bn)–
PER–
PBR–
ROE %-182.4
Debt ratio % (liabilities / equity)109
Revenue TTM (KRW bn)7.1
Op. profit TTM (KRW bn)-36.8
Dividend yield %–
Basis: market cap at …; equity = total equity (consolidated if available) at 2026.06.30; net income = trailing 12 months to 2026.06.30 (consolidated). PER is not shown when TTM net income is negative.
Upcoming risk events
Next 90 days for this company, plus macro events tagged with this ticker or its sector. Not a recommendation.
| 2026-11-06 | Bonds with warrants (BW): conversion / exercise period starts ↗ 1.30% of shares · price ₩19,072 · refix floor ₩13,351 (70.0%) · size ₩9.0bn | Low |
| 2026-11-06 | Convertible bonds (CB): conversion / exercise period starts ↗ 1.85% of shares · price ₩19,072 · refix floor ₩13,351 (70.0%) · size ₩12.8bn | Low |
| 2026-12-03 | New share sales (rights offerings): payment date ↗ 18.68% of shares · price ₩14,310 · size ₩105.8bn · 주주배정후 실권주 일반공모 | High |
| 2026-12-17 | New share sales (rights offerings): new shares listed ↗ 18.68% of shares · price ₩14,310 · size ₩105.8bn · 주주배정후 실권주 일반공모 | High |
Annual results (KRW bn)
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Revenue | 4.9 | 8.5 | 9.0 | 9.2 | 7.0 |
| Operating profit | -24.2 | -27.5 | -23.2 | -27.5 | -29.8 |
| Net income | -23.7 | -27.1 | -22.2 | -25.0 | -31.3 |
Quarterly results (KRW bn, 3 months)
| 2025Q1 | 2025Q2 | 2025Q3 | 2025Q4 | 2026Q1 | 2026Q2 | |
|---|---|---|---|---|---|---|
| Revenue | 1.9 | 1.8 | 1.7 | 1.5 | 1.9 | 1.9 |
| Operating profit | -6.7 | -6.8 | -7.0 | -9.3 | -7.7 | -12.8 |
| Net income | -6.2 | -6.4 | -6.6 | -12.1 | -7.9 | -13.2 |
Largest shareholder
As of the 2025 annual report: (주)동구바이오제약 and related parties hold 10.82% of common shares.
Recent disclosures
| Date | Filing | Summary | |
|---|---|---|---|
| 2026-10-16 | Governance / misc. (routine) 권리락 (유상증자) | DART original | |
| 2026-10-16 | Securities registration / prospectus 유상증자1차발행가액결정 | DART original | |
| 2026-10-16 | Securities registration / prospectus 투자설명서 | DART original | |
| 2026-10-16 | Securities registration / prospectus [발행조건확정]증권신고서(지분증권) | DART original | |
| 2026-10-16 | Rights offering (paid-in capital increase) [기재정정]주요사항보고서(유상증자결정) | DART original | |
| 2026-10-15 | Insider / major-holder ownership report 임원ㆍ주요주주특정증권등거래계획보고서 | DART original | |
| 2026-10-13 | IR event 기업설명회(IR)개최 | DART original | |
| 2026-10-16 | Securities registration / prospectus 효력발생안내( 2026.9.29. 제출 증권신고서(지분증권) ) | DART original | |
| 2026-09-29 | Securities registration / prospectus [기재정정]증권신고서(지분증권) | DART original | |
| 2026-09-29 | Rights offering (paid-in capital increase) [기재정정]주요사항보고서(유상증자결정) | DART original | |
| 2026-09-22 | IR event 기업설명회(IR)개최 | DART original | |
| 2026-09-22 | IR event 기업설명회(IR)개최 | DART original |
Past material filings and price reaction (market-adjusted)
| Date | Filing type | On the news (vs. market) | Next day (vs. market) | 20 days (vs. market) |
|---|---|---|---|---|
| 2026-09-04 | Rights offering (paid-in capital increase) | +14.4% | +10.6% | -5.5% |
| 2026-02-11 | Revenue/profit change >=30% (15% large caps) | -2.1% | -0.0% | +18.8% |
| 2025-12-29 | Clinical trial / regulatory approval | +0.4% | -0.4% | -8.4% |
| 2025-12-19 | Rights offering (paid-in capital increase) | -0.9% | -1.6% | -8.0% |
| 2025-12-18 | Acquisition of shares in another company | -0.9% | -1.6% | -8.0% |
| 2025-11-25 | Clinical trial / regulatory approval | +0.7% | +7.0% | +10.3% |
| 2025-10-29 | BW/EB issuance | +0.4% | +0.0% | +39.0% |
| 2025-10-29 | Convertible bond issuance | +0.4% | +0.0% | +39.0% |
| 2025-09-25 | Other material event (investment-relevant) | +6.7% | +1.9% | +14.3% |
| 2025-07-29 | Clinical trial / regulatory approval | +1.6% | +0.4% | +3.8% |
For information only, not investment advice. Data may be delayed or inaccurate. Full disclaimer → Data: OpenDART (FSS), stock prices: official previous-day close from the Financial Services Commission (data.go.kr) and FinanceData/marcap history, index data via FinanceDataReader, FX: ECB reference rates, crypto data from Upbit, Bithumb and Binance public APIs.
Market data not licensed for redistribution.
© Crypvu · Crypto market view
Market data not licensed for redistribution.
© Crypvu · Crypto market view